Guardant Health, Pangaea Biotech, the Dr. Rosell Oncology Institute and MedSIR Announce a Strategic Collaboration to Study Liquid Biopsy in Spain
REDWOOD CITY, CALIF., and BARCELONA, May 18 2016 - Guardant Health, Pangaea Biotech, the Dr. Rosell Oncology Institute (IOR) and MedSIR announced a strategic collaboration to study liquid biopsy from cancer patients in Spain.
“Guardant360 has already helped thousands of patients avoid the costs, complications and delays of invasive biopsy procedures,” said Helmy Eltoukhy, Guardant Health CEO. “Pangaea and MedSIR have strong track records in clinical trial design and execution in Spain and are ideal partners for Guardant Health.”
Guardant Health will provide its Guardant360 liquid biopsy test, while MedSIR will serve as the sponsor in Spain and Pangaea as the central lab. The Dr. Rosell Oncology Institute, with a strong presence in hospitals from the Quirónsalud group, is one of the primary centers driving patient recruitment.
“Comprehensive liquid biopsy technology like Guardant Health’s that can achieve both high sensitivity and high specificity has the potential to help us identify all of the growing list of mutations that can be targeted with matched therapy,” said Dr. Rafael Rosell, Director of the Cancer Biology and Precision Medicine Program at the Catalan Institute of Oncology in Barcelona, as well as co-founder of Pangaea Biotech and IOR. “Guardant Health’s commitment to rigorously study this technology will support its broad adoption by oncologists.”
“This agreement with Guardant Health is the start of a long-lasting partnership with one of the most important global players in next-generation sequencing of liquid biopsy" said Javier Rivela, Pangaea Biotech CEO. “We believe that by joining forces with MedSIR, a unique clinical trial design and management company and a strategic partner for us, we have a solid team to take on this innovative project.”
About Guardant Health
Guardant Health, headquartered in Redwood City, Calif., is focused on developing breakthrough diagnostics that can transform cancer from a silent killer into a manageable disease. Guardant Health was founded in 2012 by a team of serial entrepreneurs with expertise in next-generation sequencing, single-cell genomics, and cancer diagnostics. The team is committed to positively and significantly impacting patient health through technology that addresses long-standing unmet needs in oncology.
About Pangaea Biotech
Pangaea Biotech S.L is a biotechnology company led by world-renowned oncologist Dr Rafael Rosell. Founded in 2007, Pangaea has grown rapidly to become a reference laboratory in its field and has established client relationships with some of the largest global pharmaceutical, diagnostics and biotech companies. Pangaea has three main areas of activity: development of diagnostic tools and services - with a special focus on Liquid Biopsy - development of new anti-cancer drugs, and patient care provided by the Dr Rosell Oncology Institute (IOR) located in Quirón Dexeus University Hospital, Barcelona, Sagrat Cor University Hospital, Barcelona, and University Hospital General de Cataluyna, Sant Cugat dels Valles. Both Pangaea and IOR are highly experienced in the field of clinical trials and offer a dedicated Clinical Trials Unit and comprehensive molecular diagnostics and pathology testing services.
Medica Scientia Innovation Research, MedSIR, is an Academic Research Organization founded in 2012 whose core activity is the design and management of investigator-initiated clinical studies. Through its international network of clinical experts, MedSIR seeks to identify the most innovative, strategic, and clinically relevant ideas for clinical trials that will benefit patients, add to scientific knowledge, and boost product development. Based in Barcelona, MedSIR applies an international focus to all of its activities, be it the identification of strategic ideas or securing the participation of top international centers in its clinical studies. Since it was founded, MedSIR has successfully launched and managed clinical studies in tumors such as breast, lung and endometrial, with a focus on the early strategic phases of clinical development.